153 related articles for article (PubMed ID: 32865779)
1. Invention and Early History of Gapmers.
Lim KRQ; Yokota T
Methods Mol Biol; 2020; 2176():3-19. PubMed ID: 32865779
[TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Applications of Antisense Oligonucleotide Gapmers.
Chan L; Yokota T
Methods Mol Biol; 2020; 2176():21-47. PubMed ID: 32865780
[TBL] [Abstract][Full Text] [Related]
3. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers.
Maruyama R; Yokota T
Methods Mol Biol; 2020; 2176():49-56. PubMed ID: 32865781
[TBL] [Abstract][Full Text] [Related]
4. Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy.
Aslesh T; Yokota T
Methods Mol Biol; 2020; 2176():69-85. PubMed ID: 32865783
[TBL] [Abstract][Full Text] [Related]
5. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
[TBL] [Abstract][Full Text] [Related]
6. Fine-tuning of ENA gapmers as antisense oligonucleotides for sequence-specific inhibition.
Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
Oligonucleotides; 2007; 17(3):291-301. PubMed ID: 17854269
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus.
Okamoto S; Echigoya Y; Tago A; Segawa T; Sato Y; Itou T
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834294
[TBL] [Abstract][Full Text] [Related]
8. Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice.
Hagedorn PH; Pontoppidan M; Bisgaard TS; Berrera M; Dieckmann A; Ebeling M; Møller MR; Hudlebusch H; Jensen ML; Hansen HF; Koch T; Lindow M
Nucleic Acids Res; 2018 Jun; 46(11):5366-5380. PubMed ID: 29790953
[TBL] [Abstract][Full Text] [Related]
9. Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease.
Aslesh T; Yokota T
Methods Mol Biol; 2020; 2176():57-67. PubMed ID: 32865782
[TBL] [Abstract][Full Text] [Related]
10. Gapmer Antisense Oligonucleotides Containing 2',3'-Dideoxy-2'-fluoro-3'-C-hydroxymethyl-β-d-lyxofuranosyl Nucleotides Display Site-Specific RNase H Cleavage and Induce Gene Silencing.
Danielsen MB; Lou C; Lisowiec-Wachnicka J; Pasternak A; Jørgensen PT; Wengel J
Chemistry; 2020 Jan; 26(6):1368-1379. PubMed ID: 31682037
[TBL] [Abstract][Full Text] [Related]
11. Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.
Kasuya T; Hori S; Watanabe A; Nakajima M; Gahara Y; Rokushima M; Yanagimoto T; Kugimiya A
Sci Rep; 2016 Jul; 6():30377. PubMed ID: 27461380
[TBL] [Abstract][Full Text] [Related]
12. Use of GapmeRs for gene expression knockdowns in human primary resting CD4+ T cells.
Abewe H; Deshmukh S; Mukim A; Beliakova-Bethell N
J Immunol Methods; 2020 Jan; 476():112674. PubMed ID: 31629740
[TBL] [Abstract][Full Text] [Related]
13. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
Rapozzi V; Cogoi S; Xodo LE
Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454
[TBL] [Abstract][Full Text] [Related]
14. Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression.
Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
Nucleic Acids Symp Ser (Oxf); 2006; (50):319-20. PubMed ID: 17150946
[TBL] [Abstract][Full Text] [Related]
15. Role of Computationally Evaluated Target Specificity in the Hepatotoxicity of Gapmer Antisense Oligonucleotides.
Kasuya T; Kugimiya A
Nucleic Acid Ther; 2018 Oct; 28(5):312-317. PubMed ID: 30095329
[TBL] [Abstract][Full Text] [Related]
16. Design of antisense oligonucleotides stabilized by locked nucleic acids.
Kurreck J; Wyszko E; Gillen C; Erdmann VA
Nucleic Acids Res; 2002 May; 30(9):1911-8. PubMed ID: 11972327
[TBL] [Abstract][Full Text] [Related]
17. 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo.
Prakash TP; Johnston JF; Graham MJ; Condon TP; Manoharan M
Nucleic Acids Res; 2004; 32(2):828-33. PubMed ID: 14762210
[TBL] [Abstract][Full Text] [Related]
18. Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA.
Frieden M; Christensen SM; Mikkelsen ND; Rosenbohm C; Thrue CA; Westergaard M; Hansen HF; Ørum H; Koch T
Nucleic Acids Res; 2003 Nov; 31(21):6365-72. PubMed ID: 14576324
[TBL] [Abstract][Full Text] [Related]
19. Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids.
Lima WF; Crooke ST
Biochemistry; 1997 Jan; 36(2):390-8. PubMed ID: 9003192
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Gene Expression Knock-Down by Chemically and Structurally Modified Gapmer Antisense Oligonucleotides.
Lisowiec-Wąchnicka J; Danielsen MB; Nader EA; Jørgensen PT; Wengel J; Pasternak A
Chembiochem; 2022 Aug; 23(15):e202200168. PubMed ID: 35675170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
